Literature DB >> 25778934

Prolonged inductive effect of rifampicin on linezolid exposure.

Cristina Gervasoni1, Francesco R Simonetti, Chiara Resnati, Nitin Charbe, Emilio Clementi, Dario Cattaneo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25778934     DOI： 10.1007/s00228-015-1833-z

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  9 in total

1.  Linezolid and rifampin: Drug interaction contrary to expectations?

Authors:  Hannes Egle; Rainer Trittler; Klaus Kümmerer; Sebastian W Lemmen
Journal:  Clin Pharmacol Ther       Date:  2005-05       Impact factor: 6.875

2.  Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin.

Authors:  Benjamin C Gebhart; Brian C Barker; Boaz A Markewitz
Journal:  Pharmacotherapy       Date:  2007-03       Impact factor: 4.705

3.  Decreased serum linezolid concentrations in two patients receiving linezolid and rifampicin due to bone infections.

Authors:  Irma Hoyo; Juan Martínez-Pastor; Sebastian Garcia-Ramiro; Consuelo Climent; Mercé Brunet; Marta Cuesta; Josep Mensa; Alex Soriano
Journal:  Scand J Infect Dis       Date:  2012-03-04

4.  Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients.

Authors:  H-Y Dong; J Xie; L-H Chen; T-T Wang; Y-R Zhao; Y-L Dong
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-02-12       Impact factor: 3.267

5.  Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design.

Authors:  M L Reitman; X Chu; X Cai; J Yabut; R Venkatasubramanian; S Zajic; J A Stone; Y Ding; R Witter; C Gibson; K Roupe; R Evers; J A Wagner; A Stoch
Journal:  Clin Pharmacol Ther       Date:  2010-12-29       Impact factor: 6.875

6.  Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism.

Authors:  Kuan Gandelman; Tong Zhu; Odette A Fahmi; Paul Glue; Kenny Lian; R Scott Obach; Bharat Damle
Journal:  J Clin Pharmacol       Date:  2010-04-06       Impact factor: 3.126

7.  Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients.

Authors:  Federico Pea; Pierluigi Viale; Piergiorgio Cojutti; Barbara Del Pin; Eleonora Zamparini; Mario Furlanut
Journal:  J Antimicrob Chemother       Date:  2012-05-02       Impact factor: 5.790

8.  Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid.

Authors:  Alex Soriano; Mar Ortega; Sebastián García; Georgina Peñarroja; Albert Bové; Miguel Marcos; Juan C Martínez; José A Martínez; Josep Mensa
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

9.  Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections.

Authors:  Dario Cattaneo; Giovanna Orlando; Valeria Cozzi; Laura Cordier; Sara Baldelli; Stefania Merli; Serena Fucile; Cecilia Gulisano; Giuliano Rizzardini; Emilio Clementi
Journal:  Int J Antimicrob Agents       Date:  2013-04-04       Impact factor: 5.283
  9 in total
  1 in total

1.  Does the conventional dosage of linezolid necessitate therapeutic drug monitoring?-Experience from a prospective observational study.

Authors:  Jie Fang; Congqin Chen; Yan Wu; Min Zhang; Ying Zhang; Guochao Shi; Yijin Yao; Hong Chen; Xiaolan Bian
Journal:  Ann Transl Med       Date:  2020-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.